+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06026657

Study of Gemcitabine and TGFb2-imprinted Natural Killer Cells With or Without Naxitamab for Treating Adults with Metastatic GD2-Expressing, HER2 Negative Breast Cancer

Led by Margaret Gatti-Mays · Updated on 2026-07-23

42

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying a treatment approach for patients with metastatic, GD2 expressing, HER2 negative breast cancer. This phase IbII trial is testing the safety and best dose of gemcitabine combined with ex vivo expanded allogenic universal donor TGF-beta imprinted natural killer TGFBi NK cells, with or without the monoclonal antibody naxitamab. The goal is to evaluate how well these treatments work together to kill tumor cells and improve patient outcomes in this advanced breast cancer. Participants are assigned to one of four groups receiving different combinations of treatments. All receive gemcitabine intravenously on days 1, 8, and 15 of each 28-day cycle for up to one year, unless disease progression or unacceptable toxicity occurs. TGFBi NK cells are given intravenously on day 16 or on days 16 and 18 of the first cycle, depending on the group. Some groups also receive naxitamab intravenously on days 1, 4, and 8 of each cycle. Throughout the study, patients undergo computed tomography CT scans and blood sample collections, and may have magnetic resonance imaging MRI. Participants are closely monitored for safety and response to treatment, including tracking adverse events and disease progression for up to one year after treatment. Researchers assess tumor response using imaging and record immune system activity through blood tests. Follow-up visits occur within 30 days after treatment ends and every three months for a year to evaluate ongoing effects and progression-free survival. Overall, the study lasts up to about one year of treatment plus one year of follow-up.

CONDITIONS

Brief Title

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Research Team

T

The Ohio State University Comprehensive Cancer Center

A

Amanda Kabetso

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here